Nasdaq:PCRX
Pacira BioSciences, Inc.
A biopharmaceutical leader in injectable drug delivery systems targeting pain management and weight loss markets with a strong cash position and growing revenue base.
Key Metrics
Investment Thesis
Bull Case
Investors may buy PCRX due to its strong revenue growth trajectory and successful transition back to profitability with a healthy operating cash flow. The company's leadership in the high-growth obesity and pain markets offers significant upside potential as new products enter commercialization phases. A substantial cash reserve of $158.5M provides flexibility for strategic acquisitions or sustained R&D without immediate dilution.
Bear Case
Concerns persist regarding the elevated long-term debt of $372.2M and a retained earnings deficit of -$199.3M, which could constrain future growth initiatives. The volatility in net income, swinging from a loss in 2024 to a modest profit in 2025, suggests earnings instability typical of early-stage biotech commercialization. High operating expenses relative to revenue may pressure margins if market penetration for new products does not accelerate as expected.
About Pacira BioSciences, Inc.
Pacira BioSciences develops and commercializes first-in-class injectable drug delivery systems that address unmet needs in pain management, weight loss, and rare diseases. The company primarily serves the global markets for chronic pain and obesity through its leading product, Xyosted, while expanding into pediatric and adult rare disease indications. Revenue growth is driven by the commercialization of its proprietary platforms across these therapeutic areas.
Analysis
Management Discussion
Recent financial performance shows a recovery to positive net income of $7.0M in 2025 following a loss in 2024, driven by robust revenue growth to $726.4M. However, operating expenses remain elevated at $557.5M, reflecting continued investment in R&D ($117.3M) and general administration ($368.8M). Cash flow from operations turned positive at $152.0M, partially offset by substantial cash outflows for share repurchases ($148.3M) and financing activities.
Industry Overview
The global drug delivery and pain management industry is experiencing rapid expansion driven by an aging population and rising obesity rates, creating substantial demand for innovative solutions. Biopharmaceutical companies are increasingly focusing on injectable platforms that offer sustained release mechanisms to improve patient compliance and therapeutic outcomes. Regulatory pathways in the US and Europe continue to evolve, impacting approval timelines and market access strategies for novel therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $666.8M | $675.0M | $0 | $726.4M |
| Cost of Revenue | $199.3M | $184.7M | $170.4M | $149.7M |
| Gross Profit | $467.5M | $490.3M | $-170.4M | $576.7M |
| Operating Expenses | $407.5M | $402.6M | $-97.1M | $557.5M |
| Operating Income | $60.0M | $87.7M | $-73.4M | $19.2M |
| R&D | $84.8M | $76.3M | $81.6M | $117.3M |
| G&A | $254.5M | $269.4M | $294.1M | $368.8M |
| Stock-Based Comp | $48.1M | $47.9M | $51.2M | $57.5M |
| D&A | $91.5M | $75.6M | $78.8M | $91.0M |
| Depreciation | $34.2M | $18.3M | $21.5M | $33.7M |
| Amortization | $57.3M | $57.3M | $57.3M | $57.3M |
| Other OpEx | $68.2M | $56.9M | $-472.7M | $71.4M |
| Non-Operating Income | $-46.7M | $-26.0M | $10.3M | $-2.3M |
| Interest Expense | $40.0M | $20.3M | — | — |
| Interest Income | $4.5M | $11.4M | $19.7M | $22.7M |
| Pre-Tax Income | $13.3M | $61.7M | $-63.1M | $16.9M |
| Income Tax | $-2.6M | $19.7M | $36.5M | $9.8M |
| Continuing Ops | $15.9M | $42.0M | $-99.6M | $7.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $15.9M | $42.0M | $-99.6M | $7.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $15.9M | $42.0M | $-99.6M | $7.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $498.3M | $510.0M | $745.1M | $548.0M |
| Cash & Equivalents | $104.1M | $153.3M | $276.8M | $158.5M |
| Marketable Securities | $184.5M | $125.3M | $207.8M | $79.9M |
| Accounts Receivable | $98.4M | $105.6M | $113.3M | $124.1M |
| Inventory | $96.1M | $104.4M | $125.3M | $152.9M |
| Prepaid Expenses | $15.2M | $21.5M | $21.9M | $32.6M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $1.18B | $1.06B | $808.4M | $716.9M |
| PP&E (Net) | $183.5M | $173.9M | $167.2M | $140.7M |
| Intangibles | $540.5M | $483.3M | $426.0M | $368.1M |
| Goodwill | $163.2M | $163.2M | $0 | $20.2M |
| Operating Leases | $70.9M | $61.0M | $49.2M | $41.8M |
| LT Investments | $37.2M | $2.4M | $0 | — |
| Other LT Assets | $187.5M | $180.5M | $166.0M | $146.2M |
| Total Assets | $1.68B | $1.57B | $1.55B | $1.26B |
| Current Liabilities | $147.8M | $97.4M | $309.9M | $120.6M |
| Accounts Payable | $15.2M | $15.7M | $19.1M | $15.2M |
| Current Debt | — | — | — | $0 |
| Current Leases | $9.1M | $8.8M | $8.9M | $9.8M |
| Taxes Payable | — | — | $700.0K | $100.0K |
| Other Current Liab | $33.6M | $8.6M | $201.1M | $-100.0K |
| Long-Term Liabilities | $758.4M | $606.9M | $465.2M | $451.2M |
| Long-Term Debt | — | — | — | $372.2M |
| LT Operating Leases | $64.8M | $54.8M | $44.6M | $36.2M |
| Other LT Liab | $693.6M | $552.1M | $420.6M | $42.9M |
| Total Liabilities | $906.2M | $704.3M | $775.2M | $571.8M |
| Shareholders' Equity | $775.0M | $870.1M | $778.3M | $693.1M |
| Paid-In Capital | $924.1M | $976.6M | $1.01B | $1.06B |
| Retained Earnings | $-148.8M | $-106.8M | $-206.4M | $-199.3M |
| AOCI | $-380.0K | $247.0K | $343.0K | $4.3M |
| Total L&E | $1.68B | $1.57B | $1.55B | $1.26B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $15.9M | $42.0M | $-99.6M | $7.0M |
| Non-Cash Adjustments | $141.2M | $108.3M | $235.4M | $104.2M |
| Working Capital Changes | $-11.8M | $4.4M | $53.6M | $40.8M |
| Cash from Operations | $145.3M | $154.6M | $189.4M | $152.0M |
| Capital Expenditures | $30.1M | $15.2M | $10.6M | $15.3M |
| Cash from Investing | $-225.2M | $77.5M | $-83.3M | $99.5M |
| Share Buybacks | — | — | $25.0M | $148.3M |
| Cash from Financing | $-401.5M | $-183.0M | $17.4M | $-369.6M |
| FX Effect | $0 | $0 | $0 | $-77.0K |
| Net Change in Cash | $-481.4M | $49.2M | $123.5M | $-118.2M |
| Beginning Cash | $585.6M | $104.1M | $153.3M | $276.8M |
| Ending Cash | $104.1M | $153.3M | $276.8M | $158.5M |
Frequently Asked Questions
How does Pacira BioSciences, Inc. make money?
The company's revenue is generated through two primary segments: Commercial, which includes sales of Xyosted for chronic pain and emerging products for weight management; and Research & Development, covering pipeline investments in rare diseases and novel delivery technologies. Financials indicate a heavy reliance on commercial operations with significant operating expenses allocated to G&A and R&D activities.
What are the main risks for PCRX?
Regulatory approval uncertainties for new products could delay revenue recognition or require costly clinical trial resubmissions. The company faces significant competition from large pharma giants entering the obesity and pain markets with generic alternatives or biosimilars. High cash burn in R&D and potential volatility in stock-based compensation impacts future profitability projections.
What is PCRX's competitive advantage?
Pacira possesses a robust intellectual property portfolio protecting its proprietary injectable drug delivery platforms, creating a high barrier to entry for competitors. The company benefits from a first-mover advantage in specific niche markets for chronic pain and obesity, allowing for premium pricing and rapid market capture. Its diversified pipeline across multiple therapeutic areas reduces reliance on a single product line.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.